BioSpace News Archive

Akeso, Inc. published encouraging preclinical results in poster featuring its Fc-mutant anti-TIGIT antibody fused with TGF-βRII protein at the European Society for Medical Oncology Congress 2022.

ONWARD Medical N.V. announced that the Up-LIFT pivotal study evaluating ARC-EX Therapy achieved its primary effectiveness endpoint of improvement in upper extremity strength and function. ARC-EX Therapy is a proprietary non-invasive spinal cord stimulation technology designed to restore movement and other functions in people with movement disabilities.

IRLAB Therapeutics IRLAB Therapeutics AB, a clinical-stage biopharmaceutical company discovering and developing novel treatments for the most troublesome symptoms of Parkinson’s disease, announced that Richard Godfrey, CEO of IRLAB, will present at ABGSC Investor Day on Tuesday, September 13, 2022, at 16:30 am CEST.

Akero Therapeutics, Inc., a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, released topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin in patients with pre-cirrhotic nonalcoholic steatohepatitis, fibrosis stage 2 or 3.

Virtuoso Surgical, Inc., a Nashville-based medical device company, announced today that its $20 million stock offering has become effective after review by the United States Securities and Exchange Commission and the Financial Industry Regulatory Authority.

The International Society for Heart and Lung Transplantation and the European Society for Organ Transplantation have collaborated to offer an Academy course on Mechanical Circulatory Support on 13 November, concurrently with the first day of the ESOT TLJ 3.0 Consensus Conference.

ANGLE plc, a world-leading liquid biopsy company, is delighted to announce that its United States clinical laboratory team presented a new poster at the 100th American Society for Clinical Pathology meeting in Chicago, Illinois, USA between 7-9 September 2022.

Sight Sciences, Inc. announced the completion of enrollment in the SAHARA Trial, a first of its kind outcomes study designed to evaluate whether an interventional dry eye procedure with the TearCare System is superior in alleviating the signs and symptoms of dry eye disease compared to 6-months of twice daily Restasis® dry eye eyedrops.

Anteris Technologies Ltd announced the presentation of clinical data from its first-in-human trial for DurAVR™ at the annual meeting of the Transcatheter Cardiovascular Therapeutics medical conference to be held in Boston September 16-19, 2022.

Ventris Medical, a privately held orthobiologics and tissue regeneration company, announced that the United States Food and Drug Administration has granted 510 clearance for Synthetic Bone Graft Putty.